1-methyl-3-isobutylxanthine has been researched along with beraprost in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horie, S; Ishii, H; Kazama, M; Kizaki, K; Uchiyama, H | 1 |
| Kainoh, M; Maruyama, I; Nakadate, T; Nishio, S | 1 |
2 other study(ies) available for 1-methyl-3-isobutylxanthine and beraprost
| Article | Year |
|---|---|
Cyclic AMP increases thrombomodulin expression on membrane surface of cultured human umbilical vein endothelial cells.
Topics: 1-Methyl-3-isobutylxanthine; Bucladesine; Cell Membrane; Cells, Cultured; Cyclic AMP; Endothelium, Vascular; Epoprostenol; Humans; Platelet Aggregation Inhibitors; Receptors, Cell Surface; Receptors, Thrombin; Tetradecanoylphorbol Acetate; Thrombin | 1990 |
Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level.
Topics: 1-Methyl-3-isobutylxanthine; Bucladesine; Cell Membrane; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Endothelium, Vascular; Epoprostenol; Humans; In Vitro Techniques; Interleukin-1; Receptors, Cell Surface; Receptors, Thrombin; Tumor Necrosis Factor-alpha | 1991 |